Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Salam: Anti-VEG F agents for diabetic maculopathy. (0.10 sec) 

Anti-VEG F agents for diabetic maculopathy


A Salam, J DaCosta, S Sivaprasad - British Medical Journal, 2009 - bjo.bmj.com
Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ...
Related articles - All 3 versions

Anti-VEGF agents for diabetic maculopathy


AS FRCSE, JDCMS MRCOphth, SS FRCSE, C … - bjo.bmj.com
Page 1. doi: 10.1136/bjo.2009.163576 published online June 24, 2009 Br J
Ophthalmol Aysha Salam, Joanna DaCosta and Sobha Sivaprasad ...
Related articles

Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema


A Ozkiriş - Eye, 2008 - canadiancpd.medscape.com
Retinal hypoxia is the primary cause of diabetic retinopathy, which increases
expression of vascular endothelial growth factor (VEGF). As known, VEGF is a
potent inducer of vascular permeability that has been shown to cause ...
Cited by 6 - Related articles - All 8 versions

Emerging pharmacotherapies for diabetic macular edema


BA Furlani, CH Meyer, EB Rodrigues, M Maia … - Expert Opin. Emerging Drugs, 2007 - informahealthcare.com
Diabetic macular edema (DME) is the most frequent cause of severe vision
impairment in patients with non-proliferative diabetic retinopathy. Even though
patients should achieve optimal glycemic control, normalization of blood ...
Cited by 9 - Related articles - BL Direct - All 6 versions

Blood–retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features …


C Kaur, WS Foulds, EA Ling - Progress in Retinal and Eye Research, 2008 - Elsevier
The blood–retinal barrier (BRB) plays an important role in the homeostatic
regulation of the microenvironment in the retina. It consists of inner and outer
components, the inner BRB (iBRB) being formed by the tight junctions ...
Cited by 9 - Related articles - All 2 versions

Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for …

- duanesolution.com
EJ Chung, MI Roh, OW Kwon, HJ Koh - Retina, 2008 - journals.lww.com
Skip Navigation Links Home > July/August 2008 - Volume 28 - Issue 7 > Effects of
Macular Ischemia on the Outcome of Intravitreal B... ... From *Department of
Opthalmology, NHIC Ilsan Hospital, Gyounggi-do, Korea; and †The Institute ...
Cited by 9 - Related articles - All 4 versions

Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients …

- duanessolution.com
P Murugeswari, D Shukla, A Rajendran, R … - Retina, 2008 - journals.lww.com
Skip Navigation Links Home > June 2008 - Volume 28 - Issue 6 > Proinflammatory
Cytokines and Angiogenic and Anti-Angiogenic... ... From the *Department of
Immunology, Dr. G. Venkataswamy Eye Research Institute, Aravind Medical ...
Cited by 12 - Related articles - BL Direct - All 5 versions

Intravitreal bevacizumab treatment for refractory diabetic macular edema


K Örnek, N Örnek - Journal of Ocular Pharmacology and Therapeutics, 2008 - liebertonline.com
Introduction D IABETIC MACULAR EDEMA (DME) is still the main cause of visual
loss in patients with diabetic retinopathy. Treat- ment of DME includes macular
laser photocoagulation (MLP), pars plana vitrectomy (PPV), and the ...
Cited by 4 - Related articles - All 3 versions

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six- …

- prsjournal.com
DSC LAM, TYY LAI, VYW LEE, CKM CHAN, … - Retina, 2009 - journals.lww.com
From the *Department of Ophthalmology and Visual Sciences, the Chinese
University of Hong Kong, Hong Kong; †Hong Kong Eye Hospital, Kowloon, Hong
Kong; and ‡Prince of Wales Hospital, Shatin, New Territories, Hong Kong.
Cited by 3 - Related articles - All 5 versions

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser …


H Faghihi, R Roohipoor, SF Mohammadi, K Hojat … - European journal of ophthalmology - ncbi.nlm.nih.gov
PURPOSE. To evaluate the additive effect of triamcinolone to bevacizumab in
comparison to standard macular laser photocoagulation versus bevacizumab in the
management of diabetic macular edema (DME). METHODS. In a prospective, ...
Cited by 4 - Related articles


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google